bioRxivImmunologyPreprint
IFIT3 Associates with m⁶A-Modified RNA to Restrict Hepatitis C Virus Infection
Matthew G. ThompsoniD, Moonhee ParkiD, Netanya S. SchlamowitziD, Matthew R. LanahaniD, Yunsun NamiD, Stacy M. HorneriD
Abstract
Interferon-induced proteins with tetratricopeptide repeats (IFITs) are RNA-binding effectors that restrict infection by diverse RNA viruses. Among the IFIT family, how IFIT3 recognizes RNA remains the least understood. Here, we identify IFIT3 as preferentially associating with N6-methyladenosine (mA)-modified hepatitis C virus (HCV) genomic RNA and host transcripts to restrict HCV infection. IFIT3 cellular RNA binding sites and mA sites, mapped transcriptome-wide by HyperTRIBE-seq during HCV infection, showed significant overlap. This mA preference was further supported by findings that IFIT3 binding sites significantly overlapped those of established mA-binding proteins; that inhibiting mA installation reduced IFIT3 association with mA-modified HCV RNA and cellular transcripts; that IFIT3 co-purified more efficiently with mA-modified short RNA probes than with unmodified controls; and that mutating mA consensus motifs in the HCV genome reduced IFIT3 association with viral RNA. Structure-function analyses identified two regions required for RNA probe binding: tetratricopeptide repeat domains 1-2 (TPR1-2) and a previously uncharacterized predicted helical hairpin between TPRs 6 and 7. In infected cells, the helical hairpin was required for IFIT3 association with HCV RNA but dispensable for interactions with other IFIT proteins. Conversely, TPR1-2 was dispensable for HCV RNA binding but essential for IFIT2 interaction, establishing that these functions are structurally separable. Loss of either region diminished antiviral activity, as indicated by increased levels of HCV RNA in clarified supernatants. Consistent with models of mA-linked restriction of late stages of infection, extracellular HCV RNA showed reduced mA and decreased IFIT3 association relative to intracellular RNA. Together, these findings define an mA-linked mechanism by which IFIT3 engages viral RNA and reveal an unexpected role for mA in antiviral effector function. SIGNIFICANCERNA-binding proteins are critical effectors of antiviral defense, yet for many of these proteins the mechanisms of viral RNA recognition remain unclear. Here, we show that m6A modification on both host and viral RNA promotes recognition by the interferon stimulated gene, IFIT3. RNA recognition did not require interaction with IFIT1 or IFIT2, although IFIT3 antiviral function required both RNA binding and interaction with IFIT2. These findings identify m6A as a new regulator of IFIT protein function and broaden our understanding of how RNA modifications shape antiviral restriction.
- organism: human
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- N6-methyladenosine modification of HIV-1 RNA evades RIG-I-mediated sensing to suppresses type-I interferon induction in monocytic cells
- Cap-related modifications of RNA regulate binding to IFIT proteins
Jingping Geng, Magdalena Chrabąszczewska, … Renata Grzela·RNAPeer-reviewed·Jul 15, 2024
- The m6A methyltransferase complex protein VIRMA engages hepatitis C virus RNA through a WTAP-independent mechanism
Katherine M. Bland, Jordan V Reaves, … Stacy M. Horner·bioRxiv·Sep 12, 2026
- WTAP targets the METTL3 m6A-methyltransferase complex to cytoplasmic hepatitis C virus RNA to regulate infection
M. T. Sacco, K. M. Bland, S. M. Horner·bioRxiv·Jun 27, 2022
- N6-methyladenosine (m6A) RNA modifications control the antiviral response to influenza A virus infection by limiting IFITM2/3 expression
Piotr Kwiatkowski, Liudmila A Mikheeva, … Chad M. Swanson·bioRxiv·Oct 2, 2026
- N6-methyladenosine Binding Proteins Negatively Regulate HIV-1 Infectivity and Viral Production
W. Lu, N. Tirumuru, … L. Wu·bioRxiv·Mar 1, 2018